Topic Hub
8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 8 of 8 clinical reviews.
Is compounding eszopiclone (Lunesta) legal? A detailed review of FDA approval history, Schedule IV classification, 503A and 503B pharmacy rules, and current regulatory status for prescribers and patients.
Read clinical reviewEszopiclone (Lunesta) received FDA approval in 2004 but was refused by the EMA in 2009. This article compares both regulatory decisions, the clinical evidence reviewed, dose changes, and what the split means for patients.
Read clinical reviewA clinical review of eszopiclone (Lunesta) safety signals reported through the FDA Adverse Event Reporting System (FAERS), including complex sleep behaviors, next-morning impairment, and the 2019 boxed warning.
Read clinical reviewA full breakdown of Lunesta (eszopiclone) FDA approval history, label changes, safety updates, and post-market surveillance data, reviewed by the HealthRX medical team.
Read clinical reviewA complete guide to eszopiclone (Lunesta) regulatory history across the FDA, DEA, and international agencies, including current label warnings, scheduling, and post-market safety updates.
Read clinical reviewA complete review of every FDA label change to Lunesta (eszopiclone) from 2020 through 2026, including dosing revisions, boxed-warning language, complex-sleep-behavior warnings, and post-market safety signals tracked by FDA Sentinel.
Read clinical reviewA complete timeline of Lunesta (eszopiclone) patent litigation, Paragraph IV ANDA challenges, FDA dose revisions, and generic entry. Covers Hatch-Waxman disputes, safety label changes, and the 2019 boxed warning.
Read clinical reviewA clinical review of eszopiclone (Lunesta) regulatory history, current FDA label requirements, post-market safety signals, and next-generation sleep medications in the pipeline.
Read clinical review